Today represents a significant milestone for Triveni as we close a $115 Million Series B Financing – led by Goldman Sachs Alternatives – to expand our pipeline of novel therapies for I&I disorders like #atopicdermatitis. Read more: https://bit.ly/4epr5GN Learn more about Triveni: https://triveni.bio/ #biotech #precisionmedicine #immunology #inflammation
About us
Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact. To learn more, visit www.triveni.bio.
- Website
-
https://www.triveni.bio
External link for Triveni Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Watertown, MA
- Type
- Privately Held
Locations
-
Primary
Get directions
99 Coolidge Avenue
Watertown, MA 02472, US
Employees at Triveni Bio
Updates
-
Today, Triveni Bio's senior management participated in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit, where they provided key updates on the company's lead program, TRIV-509, along with other pipeline program updates. Watch a replay of the webcasted presentation here: https://lnkd.in/ejau5eQp
-
Happy to share that our redesigned website is live! Explore our team, culture, science and pipeline at the new www.triveni.bio.
-
We are thrilled to welcome Dr. Bhaskar Srivastava, M.D., Ph.D., Triveni’s new Chief Medical Officer! He arrives at a key moment of growth and evolution for the company as we advance our lead program, TRIV-509, into the clinic in the first half of 2025. Dr. Srivastava’s extensive training as a dermatologist and immunologist will further our goal of driving much needed innovation for I&I diseases. Learn more about today’s announcement here: https://bit.ly/3KHxJLC #Inflammation #Immunology #Dermatology #Innovation #Biotech
-
Exciting news from Triveni Bio after a busy week! Jennifer Dovey, our CSO, delivered an oral presentation on TRIV-509 at the Society for Investigative Dermatology’s 2024 Annual Meeting. The presentation focused on the promising results of TRIV-509 in atopic dermatitis models, demonstrating its ability to ameliorate barrier dysfunction, inflammation, and itch. Jennifer and Eva Asp, VP of Biology, also presented a poster covering the oral data in detail. Brantley Herrin, VP of Biologics, and Ye Tang, Sr. Scientist, Biologics, presented a poster on TRIV-509, our dual-specific antibody targeting KLK5 and KLK7 proteases at the PEGS 2024 Essential Protein & Antibody Engineering Summit. The poster highlighted TRIV-509's high-affinity binding at the active sites of each protease, effectively inhibiting the proteolytic activity of both. These presentations showcase the potential of TRIV-509 as a novel treatment for atopic dermatitis patients and beyond.
-